NCT05460273 · OUTCOME

Overall Survival (OS)

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Month
Interval / dispersion: 95% Confidence Interval
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

What was measured

Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.

Analysis population: FAS: Enrolled participants who have received at least one dose of treatment. Participants who were enrolled but did not subsequently receive study intervention are not included in the analysis.

Groups in this outcome

TNBC Cohort

Final Analysis with DCO on 06May2024

NSCLC Cohort

Final Analysis with DCO on 27Nov2024

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
TNBC Cohort	79
NSCLC Cohort	40

Reported measurements

Source class 1

Values in Month · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
TNBC Cohort	13.5	Not reported	10.7	NA	Upper limit not reached
NSCLC Cohort	16.7	Not reported	13.8	20.4	Not reported

Complete source fields

classes

categories
measurements
comment
Upper limit not reached
group Id
OG000
lower Limit
10.7
upper Limit
NA
value
13.5
group Id
OG001
lower Limit
13.8
upper Limit
20.4
value
16.7

denoms

counts
group Id
OG000
value
79
group Id
OG001
value
40
units
Participants

description

Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.

dispersion Type

95% Confidence Interval

groups

description
Final Analysis with DCO on 06May2024
id
OG000
title
TNBC Cohort
description
Final Analysis with DCO on 27Nov2024
id
OG001
title
NSCLC Cohort

param Type

MEDIAN

population Description

FAS: Enrolled participants who have received at least one dose of treatment. Participants who were enrolled but did not subsequently receive study intervention are not included in the analysis.

reporting Status

POSTED

time Frame

TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

title

Overall Survival (OS)

type

SECONDARY

unit Of Measure

Month

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice